>Traitement par thérapie cellulaire CAR-T en Asie-Pacifique, par produit (cellules CAR-T autologues, cellules CAR-T allogéniques), structure (cellules CAR-T de première génération, cellules Car-T de deuxième génération, cellules CAR-T de troisième génération, cellules CAR-T de quatrième génération), antigènes ciblés (antigènes sur tumeurs solides, antigènes sur hémopathies malignes, autres), marque (Yescarta, Kymriah, Tecartus, autres), application thérapeutique (hémopathies malignes, cancer du pancréas, cancer du sein, cancer du poumon, cancer gastrique , myélome multiple, leucémie lymphoïde chronique, lymphome du manteau, lymphome folliculaire, lymphome diffus à grandes cellules B, leucémie lymphoblastique aiguë, autres), utilisateur final (hôpitaux, cliniques spécialisées, autres), canal de distribution (hôpitaux, pharmacies, autres), pays (Japon, Chine, Australie, Inde, Sud) Corée, Singapour, Indonésie, Thaïlande, Malaisie, Philippines, Vietnam, reste de l'Asie-Pacifique) Tendances et prévisions du secteur jusqu'en 2028
Analyse et perspectives du marché : marché de la thérapie cellulaire CAR-T en Asie-Pacifique
Le marché du traitement par thérapie cellulaire CAR-T en Asie-Pacifique devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 30,8 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 267,08 millions USD d'ici 2028. L'augmentation de l'utilisation de la thérapie cellulaire CAR-T pour le traitement du cancer et des maladies infectieuses et la prévalence croissante du cancer sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.
Le traitement par thérapie cellulaire CAR-T comprend des caractéristiques telles que le besoin croissant de produits sûrs et efficaces aura un impact sur le lancement de nouveaux produits par les fabricants sur le marché, ce qui augmentera sa demande, ainsi que l'augmentation des investissements dans la recherche et le développement conduisant à la croissance du marché. L'augmentation des investissements dans la recherche concernant le développement de la thérapie cellulaire CAR-T devrait offrir diverses autres opportunités sur le marché du traitement par thérapie cellulaire CAR-T. Cependant, les effets secondaires indésirables des thérapies et le coût élevé associé aux thérapies devraient freiner la croissance du marché au cours de la période de prévision.
La demande de thérapie cellulaire CAR-T a augmenté dans les pays développés comme dans les pays en développement, en raison d'une sensibilisation accrue aux immunothérapies pour le traitement par thérapie cellulaire CAR-T et d'une augmentation des investissements dans la recherche et le développement. Le marché de la thérapie cellulaire CAR-T va croître au cours de la période prévue avec la prévalence croissante des cancers.
Les effets secondaires indésirables des thérapies et le coût élevé associé aux thérapies devraient freiner la croissance du marché des traitements par thérapie cellulaire CAR-T.
Le rapport sur le marché du traitement par thérapie cellulaire CAR-T fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché du traitement par thérapie cellulaire CAR-T en Asie-Pacifique
Le marché du traitement par thérapie cellulaire CAR-T est segmenté en fonction du produit, de la structure, des antigènes ciblés, de la marque, de l'application thérapeutique, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.
- Sur la base du produit, le marché de la thérapie cellulaire CAR-T est segmenté en cellules CAR-T autologues et cellules CAR-T allogéniques. En 2021, le segment des cellules CAR-T autologues devrait dominer le marché de la thérapie cellulaire CAR-T car les médicaments approuvés pour la thérapie cellulaire CAR-T sont de nature autologue. Ces cellules sont faciles à fabriquer car elles sont dérivées des propres cellules ou du plasma du patient. De plus, des recherches intensives sont en cours sur les cellules autologues.
- Sur la base de la structure , le marché des traitements par thérapie cellulaire CAR-T est segmenté en cellules CAR-T de première génération, cellules CAR-T de deuxième génération, cellules CAR-T de troisième génération et cellules CAR-T de quatrième génération. En 2021, le segment des cellules CAR-T de deuxième génération devrait dominer le marché des traitements par thérapie cellulaire CAR-T, car les thérapies approuvées sont basées sur la structure de deuxième génération. De plus, la deuxième génération est de nature hautement spécifique, reconnaissant et liant les antigènes spécifiques des tumeurs.
- Sur la base d' antigènes ciblés , le marché du traitement par thérapie cellulaire CAR-T est segmenté en antigènes sur tumeurs solides, antigènes sur hémopathies malignes et autres. En 2021, le segment des antigènes sur hémopathies malignes devrait dominer le marché du traitement par thérapie cellulaire CAR-T, car les médicaments approuvés pour la thérapie cellulaire CAR-T sont principalement utilisés pour les hémopathies malignes et font l'objet d'un développement de recherche approfondi.
- Sur la base de la marque, le marché des traitements par thérapie cellulaire CAR-T est segmenté en yescarta, kymriah, tecartus et autres. En 2021, le segment yescarta devrait dominer le marché des traitements par thérapie cellulaire CAR-T car yescarta est la première thérapie cellulaire CAR-T approuvée pour la classe thérapeutique oncologique. De plus, yescarta représente le chiffre d'affaires le plus élevé.
- On the basis of therapeutic application, the CAR-T cell therapy treatment market is segmented into hematological malignancies, pancreatic cancer, breast cancer, lung cancer, gastric cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia and others. In 2021, hematological malignancies segment is expected to dominate the CAR-T cell therapy treatment market because yescarta accounts the major revenue in the market and the follicular lymphoma is the major indication for yescarta.
- On the basis of end user, the CAR-T cell therapy treatment market is segmented into hospitals, specialty clinics and others. In 2021, hospitals segment is dominating the CAR-T cell therapy treatment market because CAR-T cell therapy required highly trained professionals with advanced technology laboratories. So, the hospitals have all the advanced equipment and technology with trained professionals.
- On the basis of distribution channel, the CAR-T cell therapy treatment market is segmented into hospitals pharmacy and others. In 2021, hospitals pharmacy segment is expected to dominate the CAR-T cell therapy treatment distribution channel because hospitals pharmacy are the central part of the hospitals, all the infusion related and medication related delivery sold by the pharmacy department.
CAR-T Cell Therapy Treatment Market Country Level Analysis
The CAR-T cell therapy treatment market is analyzed and market size information is provided on the basis of product, structure, targeted antigens, brand, therapeutic application, end user, distribution channel as referenced above.
The countries covered in the CAR-T cell therapy treatment market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, and Rest of Asia-Pacific.
Autologous CAR-T cells segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 due to continuous research and development related to the CAR-T cell therapy. Japan is leading the growth of the Asia-Pacific market and autologous CAR-T cells segment is dominating in this country because due to increasing healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rise in Awareness about Immunotherapies and Increasing Investment in Research and Development are Boosting the Market Growth of CAR-T Cell Therapy Treatment Market
CAR-T cell therapy treatment market also provides you with detailed market analysis for every country growth in CAR-T cell therapy treatment industry with CAR-T cell therapy treatment drugs sales, impact of advancement in the CAR-T cell therapy treatment technology and changes in regulatory scenarios with their support for the CAR-T cell therapy treatment market. The data is available for historic period 2010 to 2019.
Competitive Landscape and CAR-T Cell Therapy Treatment Market Share Analysis
CAR-T cell therapy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to CAR-T cell therapy treatment market.
The major companies which are dealing in the CAR-T cell therapy treatment are Autolus, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AbbVie Inc., Novartis AG, Cartherics Pty ltd, CARINA BIOTECH, and TC BIOPHAR Mamong others global and domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the CAR-T cell therapy treatment market.
For instance,
- In February 2021, AbbVie Inc. had announced the collaboration with the Caribou Biosciences which is the biotechnology leading company in the clinical-stage CRISPR genome editing. The companies have entered into the collaboration and license agreement for the research and development of the chimeric antigen receptor (CAR)-T cell therapeutics. The allogeneic CAR-T cell therapies showed positive impact on the cancer patients but the rejection of CAR-T cells by the host immune system has been considered as one of the challenge for the researchers therefore, Caribou Biosciences technology that is CRISPR genome editing will be engineered to the CAR-T cells so that it can endure the host immune attack which can benefit the large patient population. This collaboration helped the company to be considered in the market who is involved in the development of the innovative CAR-T therapies and overcome the issues related with this therapy which will increase the status in the market and directly increases their company growth.
- En juillet 2020, Kite Pharma (une filiale de Gilead Sciences, Inc.) a annoncé que la société avait reçu l'approbation de la FDA américaine pour Tecartus (brexucabtagene autoleucel), auparavant connu sous le nom de KTE-X19, qui était considéré comme la seule thérapie cellulaire CAR-T pour le traitement du lymphome à cellules du manteau réfractaire (MCL). Le produit a reçu la désignation de thérapie révolutionnaire (BTD) de la FDA. La perfusion unique de ce produit a révélé que 62 % des patients avaient montré une réponse complète et que 87 % avaient répondu positivement. Ce produit est considéré comme la première thérapie cellulaire pour les patients souffrant de MCL récidivant/réfractaire. Cela a aidé l'entreprise à être reconnue comme l'une des entreprises à développer une thérapie cellulaire CAR-T pour le traitement du lymphome à grandes cellules B réfractaire après les deux ou trois thérapies qui augmenteront la demande sur le marché.
La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché améliorent le marché de l'entreprise sur le marché du traitement par thérapie cellulaire CAR-T, ce qui offre également l'avantage à l'organisation d'améliorer son offre pour la thérapie cellulaire CAR-T.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET PRODUCT COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN USAGE OF CAR-T CELL THERAPY FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES
7.1.2 INCREASING PREVALENCE OF CANCER
7.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES
7.1.4 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT
7.1.5 ADOPTION OF CAR-T CELL THERAPY TREATMENT IN EMERGING MARKETS
7.2 RESTRAINTS
7.2.1 ADVERSE SIDE EFFECTS OF THERAPIES
7.2.2 HIGH COST ASSOCIATED WITH THERAPIES
7.2.3 LOGISTIC CHALLENGE ASSOCIATED WITH CAR-T THERAPIES
7.2.4 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT
7.3 OPPORTUNITIES
7.3.1 PRESENCE OF PIPELINE PRODUCTS
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
7.4 CHALLENGES
7.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
7.4.2 LACK OF SKILLED PROFESSIONALS
8 IMPACT OF COVID-19 ON ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISION FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 AUTOLOGOUS CAR-T CELLS
9.3 ALLOGENEIC CAR-T CELLS
10 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE
10.1 OVERVIEW
10.2 FIRST GENERATION CAR-T CELLS
10.3 SECOND GENERATION CAR-T CELLS
10.4 THIRD GENERATION CAR-T CELLS
10.5 FOURTH GENERATION CAR-T CELLS
11 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS
11.1 OVERVIEW
11.2 ANTIGENS ON HEMATOLOGIC MALIGNANCIES
11.2.1 CLUSTER OF DIFFERENTIATION-19 (CD-19)
11.2.2 CLUSTER OF DIFFERENTIATION-30 (CD-30)
11.2.3 CLUSTER OF DIFFERENTIATION-22 (CD-22)
11.2.4 CLUSTER OF DIFFERENTIATION-20 (CD-20)
11.2.5 CLUSTER OF DIFFERENTIATION-33 (CD-33)
11.3 ANTIGENS ON SOLID TUMORS
11.3.1 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER-2)
11.3.2 EPIDERMAL GROWTH FACTOR RECEPTORS VARIANT III (EGFRV-III)
11.3.3 MESOTHELIN (MSLN)
11.3.4 PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)
11.3.5 INTERLEUKIN-13RA2 (IL13RA2)
11.3.6 DISIALOGANGLIOSIDE 2 (GD2)
11.3.7 GLYPICAN-3 (GPC3)
11.3.8 OTHERS
11.4 OTHERS
12 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND
12.1 OVERVIEW
12.2 YESCARTA
12.3 KYMRIAH
12.4 TECARTUS
12.5 OTHERS
13 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION
13.1 OVERVIEW
13.2 FOLLICULAR LYMPHOMA
13.3 DIFFUSE LARGE B-CELL LYMPHOMA
13.4 ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)
13.5 MANTLE CELL LYMPHOMA
13.6 MULTIPLE MYELOMA
13.7 HEMATOLOGIC MALIGNANCIES
13.7.1 LEUKEMIA
13.7.2 LYMPHOMA
13.7.3 MYELOMA
13.7.4 OTHERS
13.8 LUNG CANCER
13.9 CHRONIC LYMPHOCYTIC LEUKEMIA
13.1 GASTRIC CANCER
13.11 PANCREATIC CANCER
13.12 BREAST CANCER
13.13 OTHERS
14 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 OTHERS
15 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 OTHERS
16 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET BY GEOGRAPHY
16.1 ASIA-PACIFIC
16.1.1 JAPAN
16.1.2 AUSTRALIA
16.1.3 SINGAPORE
16.1.4 CHINA
16.1.5 SOUTH KOREA
16.1.6 INDIA
16.1.7 MALAYSIA
16.1.8 THAILAND
16.1.9 INDONESIA
16.1.10 PHILIPPINES
16.1.11 VIETNAM
16.1.12 REST OF ASIA-PACIFIC
17 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 KITE PHARMA (A SUBSIDIARY OF GILEAD SCIENCES, INC.)
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 NOVARTIS AG
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 ABBVIE INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENTS
19.4 ADAPTIMMUNE THERAPEUTICS PLC
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 AMGEN INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PIPELINE PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ATARA BIOTHERAPEUTICS, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PIPELINE PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENTS
19.7 AURORA BIOPHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PIPELINE PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 AUTOLUS
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 BELLICUM PHAMACEUTICALS, INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 BIOATLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 BLUEBIRD BIO, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 BRISTOL-MYERS SQUIBB COMPANY
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 CARINA BIOTECH
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 CARTHERICS PTY LTD
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 CARTESIAN THERAPEUTICS, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 PIPELINE PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 CELLECTIS SA
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 CELYAD ONCOLOGY SA
19.17.1 COMPANY SNAPSHOT
19.17.2 PIPELINE PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 JOHNSON & JOHNSON SERVICES, INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SORRENTO THERAPEUTICS, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PIPELINE PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 TC BIOPHARM LIMITED
19.20.1 COMPANY SNAPSHOT
19.20.2 PIPELINE PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 TESSA THERAPEUTICS LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 PIPELINE PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 TMUNITY THERAPEUTICS
19.22.1 COMPANY SNAPSHOT
19.22.2 PIPELINE PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 MUSTANG BIO
19.23.1 COMPANY SNAPSHOT
19.23.2 PIPELINE PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 XYPHOS (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
19.24.1 COMPANY SNAPSHOT
19.24.2 REVENUE ANALYSIS
19.24.3 PIPELINE PRODUCT PORTFOLIO
19.24.4 RECENT DEVELOPMENTS
19.25 ZIOPHARM ONCOLOGY, INC.
19.25.1 COMPANY SNAPSHOT
19.25.2 PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Liste des tableaux
TABLE 1 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS
TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:
TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)
TABLE 4 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)
CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Ζ OF T CELL RECEPTOR COMPLEX.
TABLE 8 ASIA-PACIFIC FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 56 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 57 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 58 JAPAN ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 59 JAPAN ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 60 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 61 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 62 JAPAN HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 JAPAN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 66 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 67 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 68 AUSTRALIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 69 AUSTRALIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 70 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 71 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 72 AUSTRALIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 74 AUSTRALIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 76 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 77 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 78 SINGAPORE ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 79 SINGAPORE ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 80 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 81 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 SINGAPORE HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 SINGAPORE CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 87 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 88 CHINA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 89 CHINA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 90 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 91 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 92 CHINA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 93 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 CHINA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 96 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 97 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 98 SOUTH KOREA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 99 SOUTH KOREA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 100 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 101 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 102 SOUTH KOREA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 103 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 104 SOUTH KOREA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 105 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 107 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 108 INDIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 109 INDIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 110 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 111 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 112 INDIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 113 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 114 INDIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 115 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 116 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 117 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 118 MALAYSIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 119 MALAYSIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 120 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 121 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 122 MALAYSIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 123 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 124 MALAYSIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 125 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 127 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 128 THAILAND ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 129 THAILAND ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 130 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 131 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 132 THAILAND HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 134 THAILAND CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 135 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 136 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 137 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 138 INDONESIA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 139 INDONESIA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 140 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 141 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 142 INDONESIA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 143 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 144 INDONESIA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 145 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 146 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 147 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 148 PHILIPPINES ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 149 PHILIPPINES ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 150 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 151 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 152 PHILIPPINES HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 153 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 154 PHILIPPINES CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 155 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 156 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)
TABLE 157 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 158 VIETNAM ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 159 VIETNAM ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
TABLE 160 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)
TABLE 161 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 162 VIETNAM HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)
TABLE 163 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 164 VIETNAM CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 165 REST OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Liste des figures
FIGURE 1 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: MARKET PRODUCT COVERAGE GRID
FIGURE 11 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 AUTOLOGUS CAR-T CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET IN 2021 & 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE CAR-T CELL THERAPY TREATMENT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET
FIGURE 16 NEW CANCER CASES WORLDWIDE, (2018)
FIGURE 17 ASIA-PACIFIC CANCER INCIDENCE (2018)
FIGURE 18 CANCER DEATH BY TYPE (IN MILLION), WORLD, 2017
FIGURE 19 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2021
FIGURE 20 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2019-2028 (USD MILLION)
FIGURE 21 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 22 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 23 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2021
FIGURE 24 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2019-2028 (USD MILLION)
FIGURE 25 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2021-2028)
FIGURE 26 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE
FIGURE 27 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2021
FIGURE 28 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)
FIGURE 29 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, CAGR (2021-2028)
FIGURE 30 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, LIFELINE CURVE
FIGURE 31 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020
FIGURE 32 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020-2028 (USD MILLION)
FIGURE 33 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2020-2028)
FIGURE 34 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE
FIGURE 35 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020
FIGURE 36 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020-2028 (USD MILLION)
FIGURE 37 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, CAGR (2020-2028)
FIGURE 38 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020
FIGURE 40 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 41 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 42 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 45 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 46 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 48 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 49 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028)
FIGURE 52 ASIA-PACIFIC CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
